Australian Prescriber

Hypertension is one of the most modifiable and undertreated risk factors for preventable deaths. This editorial highlights the need for improved measurement standards, lower treatment targets and greater use of combination therapy, all anticipated in Australian guidelines currently being updated and expected in 2026.

Injectable drugs are transforming management of overweight and obesity. This article compares currently available drugs and describes their use in the complex context of weight management, including efficacy, adverse effects and limitations, and the need for long-term use to sustain weight loss.

Testing for HIV infection is recommended for people with behavioural or epidemiological risk factors and those with clinical indicator conditions. This article covers when to test and the different types of tests available in Australia.

A case report highlighting lessons from an adverse reaction and a drug interaction associated with an extended course of high-dose trimethoprim+sulfamethoxazole in a person with chronic kidney disease.

The most commonly prescribed drugs in 2024–25 based on defined daily dose, prescription counts and cost to government.

A new clinical guideline for deprescribing medicines in older people has been published.

Vistella is the first high-strength calcifediol preparation to be approved in Australia for the treatment of adults with vitamin D deficiency, dosed monthly to fortnightly.

Fenfluramine, previously approved for weight loss, is now available as an add-on therapy to manage seizures associated with Dravet syndrome or Lennox–Gastaut syndrome.